Outlook Therapeutics (OTLK) Consolidated Net Income (2015 - 2026)
Outlook Therapeutics (OTLK) reported Consolidated Net Income of -$4.5 million for Q1 2026, up 90.39% year-over-year from -$2.3 million in Q1 2025, and up 66.97% quarter-over-quarter from -$13.5 million in Q4 2025.
Outlook Therapeutics (OTLK) Consolidated Net Income (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Consolidated Net Income data on file, last reported at -$4.5 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$4.5 million, up 90.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$51.4 million (down 187.64% YoY), and the FY2025 annual result was -$62.4 million, up 17.17% from the prior year.
- Consolidated Net Income climbed to -$4.5 million in Q1 2026 per OTLK's latest filing, from -$13.5 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $44.4 million in Q2 2024 and troughed at -$114.3 million in Q1 2024.
- A 5-year average of -$17.7 million and a median of -$14.3 million in 2022 frame the typical range for Consolidated Net Income.
- On a YoY basis, Consolidated Net Income climbed as much as 314.8% in 2024 and fell as far as 1617.52% in 2024.
- A 5-year view of Consolidated Net Income shows it stood at -$15.7 million in 2022, then surged by 34.2% to -$10.3 million in 2023, then tumbled by 109.31% to -$21.6 million in 2024, then surged by 37.59% to -$13.5 million in 2025, then jumped by 66.97% to -$4.5 million in 2026.
- Business Quant data shows OTLK's Consolidated Net Income at -$4.5 million in Q1 2026, -$13.5 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Mar 31, 2025 | -46.36 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 44.41 Mn |
| Mar 31, 2024 | -114.29 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -12.99 Mn |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -17.54 Mn |
| Mar 31, 2022 | -19.70 Mn |
| Dec 31, 2021 | -13.15 Mn |
| Sep 30, 2021 | -13.40 Mn |
| Jun 30, 2021 | -12.20 Mn |